



Fragments 2015: 5th RSC-BMCS Fragment-based Drug Discovery meeting

Sunday-Tuesday, 22nd-24th March 2015
Churchill College, Cambridge, UK

Synopsis

The aim of the 5th RSC-BMCS Fragment-based Drug Discovery meeting will be to continue the focus on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programmes. The Fragment series was started in 2007 and continues with the theme, having over three-quarters of the presentations focused on case studies. The conference will include successful examples from all types of fragment-based approaches, including high concentration, NMR, SPR and X-ray screening.

Who should attend

This conference is suitable for scientists including all chemists as well as other important disciplines including biophysics, structural biology, etc. This international meeting attracts delegates from the UK, several mainland European countries, as well as from the USA, Japan, China and South Korea.

Call for Posters

The abstract submission deadline has been extended to 31st January 2015. Selected student speakers will be invited to deliver a single-slide, two-minute flash presentation prior to the poster session.

Pre-conference Workshop

A pre-conference workshop is planned to offer those new to the area of FALG/FBLG an introduction into the fundamental principles governing fragment-based drug discovery approaches. A series of four short presentations with opportunities for discussions is planned. The pre-conference workshop will only be held if sufficient interest is evident, and will be offered free-of-charge to conference attendees.

Bursaries and Sponsorship

Bursaries will be available based on sponsorship of the event. If you wish to sponsor students to expand their knowledge in this area, please contact the secretariat for further information.

Exhibitors

Those companies wishing to have a trade stand should apply early to avoid disappointment as these are limited. Exhibition stands are charged at £750 for stand space only (excludes attendees).

Venue and Travel

Churchill College is a 15-minute walk from the centre of Cambridge. Travel to Cambridge is convenient by rail as well as by road. Detailed travel information may be found on the website.

Accommodation and Dinner

Accommodation for delegates at Churchill College may be booked at the time of registration. The single study bedrooms have en-suite or shared bathrooms, and rooms will be allocated on a "first come, first served" basis. The conference dinner will be held in the 16th Century Hall of St John's College, adjacent to the historic Bridge of Sighs. Attendance at the conference dinner is included in the registration fee.

Registration is open

Early-bird rates until 19th January:	Std rates from 20 th Jan to 20 th Feb
£300 RSC member	£360 RSC member
£380 non-member	£450 non-member
£155 RSC student* member	£185 RSC student* member
£195 student* non-member	£230 student* non-member
* Student is undergraduate or PhD student, not post-doctoral student	
£50 late payment fee will apply to all payments received after 20th February.	
£120 exhibition stand staff (no access to technical sessions)	

Organising Committee


Mike Hann, GlaxoSmithKline
Samantha Hughes, AstraZeneca
Thorsten Nowak, C4X Discovery

Gordon Saxty (chair), Fidelta
Mark Whittaker, Evotec

Contact and Secretariat

RSC-BMCS Secretariat: Maggi Churchouse, 3 East Barn, Market Weston Road, Theltham, Diss IP22 1JJ, UK. Telephone and fax +44 (0)1359 221004, maggi@maggichurchousevents.co.uk

www.maggichurchousevents.co.uk/bmcs
www.RSC.org/bmcs





Detailed Programme

Sunday, 22nd March - optional pre-conference workshop

- 15:00 Introduction to FBDD (Thorsten Nowak, C4X Discovery, and Mike Hann, GlaxoSmithKline)
- 15:40 Identifying hits: fragment screening libraries and methods (Samantha Hughes, AstraZeneca)
- 16:15 Refreshments
- 16:45 Hit optimisation using fragments (Mark Whittaker, Evotec)
- 17:20 Fragments and the bigger picture (Mike Hann, GlaxoSmithKline)
- 18:00 Close

Monday, 23rd March

- 09:15 Registration and refreshments
- 10:20 Session chair: Gordon Saxty, Fidelta (HR)
Opening remarks
- 10:30 Fragments and PPIs ligandability: adventures and lessons learnt
Alessio Ciulli, University of Dundee (UK)
- 11:15 Diversity-based optimisation of halogen-enriched fragment libraries (HEFLibs)
Frank Böckler, University of Tübingen (DE)
- 12:00 Flash poster presentations
- 12:30 Lunch and posters

- 13:30 Session chair: Mike Hann, GlaxoSmithKline (UK)
Fragment-based discovery of potent BRD4-BD1 and BRD9 inhibitors
Darryl McConnell, Boehringer Ingelheim (AT)
- 14:15 Fragment-based lead generation for new targets in oncology
Nathan Fuller, AstraZeneca (US)
- 15:00 Refreshments
- 15:30 Fragment-based approach to multi-target ligands
Eugen Proschak, University of Frankfurt (DE)
- 16:15 Title to be confirmed
Speaker to be confirmed
- 17:00 Poster session and drinks reception
- 19:15 Conference dinner at St John's College

Tuesday, 24th March

- 09:00 Session chair: Mark Whittaker, Evotec (UK)
Fragment-based drug discovery for GPCRs: Results for families A to C and new computational insights to drive design
Jonathan Mason, Heptares (UK)
- 09:45 Choosing and using fragments in the generation of selective kinase inhibitors
Lee Walmsley, Vernalis R&D (UK)
- 10:30 Refreshments
- 11:00 Poised fragments for epigenetic targets
Paul Brennan, SGC (UK)
- 11:45 Identification of in vivo active BCATm inhibitors using fragment-based drug discovery
Stephen Pickett, GlaxoSmithKline (UK)
- 12:30 Lunch and posters

- 13:30 Session chair: Thorsten Nowak, C4X Discovery (UK)
Fragment library analysis and targeting protein-protein interactions
Rich Taylor, UCB (UK)
- 14:15 Fragment-based drug discovery. Sweating the small stuff is worth it
Gavin Hirst, Takeda (US)
- 15:00 Refreshments
- 15:30 The challenges of targeting protein-protein interactions in Ras-SOS with fragments
Joe Patel, AstraZeneca (US)
- 16:15 Fragment-based drug discovery PPI case history
David Rees, Astex Therapeutics (UK)
- 17:30 Closing remarks
Samantha Hughes, AstraZeneca (UK)